Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Cid

Showing results (191-200 of 288) with videos related to

Pageof 29
Sort By:
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 1992
Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cellsP Lemarchand, H A Jaffe, C Danel, et al.
European Journal of Internal Medicine|November 18, 2017
Biological treatments in giant cell arteritis & Takayasu arteritisMaxime Samson, Georgina Espígol-Frigolé, Nekane Terrades-García, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Rheumatic Diseases Clinics of North America|October 16, 2016
The Expanding Role of Imaging in Systemic VasculitisSergio Prieto-González, Georgina Espígol-Frigolé, Ana García-Martínez, et al.
Arthritis and Rheumatism|April 5, 2002
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritisJosé Hernández-Rodríguez, Ana García-Martínez, Jordi Casademont, et al.
Annals of Internal Medicine|May 2, 2007
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trialGary S Hoffman, Maria C Cid, Karen E Rendt-Zagar, et al.
Rheumatology (Oxford, England)|October 20, 2019
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosisHelena Florez, José Hernández-Rodríguez, Africa Muxi, et al.
Medicine|September 3, 2014
Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patientsMarco A Alba, Ana García-Martínez, Sergio Prieto-González, et al.
Rheumatology (Oxford, England)|April 20, 2006
Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritisM C Cid, M P Hoffman, J Hernández-Rodríguez, et al.
Pageof 29

Showing results (191-200 of 288) with videos related to

Sort By:
Pageof 29
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 1992
Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cellsP Lemarchand, H A Jaffe, C Danel, et al.
European Journal of Internal Medicine|November 18, 2017
Biological treatments in giant cell arteritis & Takayasu arteritisMaxime Samson, Georgina Espígol-Frigolé, Nekane Terrades-García, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Rheumatic Diseases Clinics of North America|October 16, 2016
The Expanding Role of Imaging in Systemic VasculitisSergio Prieto-González, Georgina Espígol-Frigolé, Ana García-Martínez, et al.
Arthritis and Rheumatism|April 5, 2002
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritisJosé Hernández-Rodríguez, Ana García-Martínez, Jordi Casademont, et al.
Annals of Internal Medicine|May 2, 2007
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trialGary S Hoffman, Maria C Cid, Karen E Rendt-Zagar, et al.
Rheumatology (Oxford, England)|October 20, 2019
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosisHelena Florez, José Hernández-Rodríguez, Africa Muxi, et al.
Medicine|September 3, 2014
Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patientsMarco A Alba, Ana García-Martínez, Sergio Prieto-González, et al.
Rheumatology (Oxford, England)|April 20, 2006
Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritisM C Cid, M P Hoffman, J Hernández-Rodríguez, et al.
Pageof 29